Pentixafor
Based on 2 publication(s) in Google Scholar
Pentixafor is a peptide that targets CXCR4. Pentixafor is capable of being labelled with 68Gallium (68Ga) for positron emission tomography (PET) imaging. Pentixafor can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 99.60%
- CAS. Nr.: 1341207-62-2
- Formel: C60H80N14O14
- Molecular Weight:1221.36
-
Speicherung:
Sealed storage, away from moisture and light.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Pentixafor
MoreAlle Radionuclide-Drug Conjugates (RDCs) Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
[18F]AlF-NOTA-Pentixather (195 pmol, 60 minutes) exhibits significant internalization and high cellular uptake in CXCR4-transfected Chem-1 cells[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
[18F]AlF-NOTA-Pentixather (0.30 MBq, intravenous injection, single dose) can target the CXCR4 receptor for specific PET imaging in the Daudi lymphoma xenograft SCID mouse model[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:PC-3 prostate cancer xenograft (nude mouse) model[2]
-
Dosage:15 MBq (Pentixafor labeled with 68Gallium (68Ga), [68Ga]Pentixafor)
-
Administration:Intravenous injection (i.v., injection via tail vein), single dose
-
Result:Resulted in moderate contrast in PET imaging performed in the PC-3 tumor model.
-
Animal Model:Daudi lymphoma xenograft (SCID mouse) model[4]
-
Dosage:0.30 MBq ([18F]AlF-NOTA-Pentixather, approx. 195 pmol/0.251 µg)
-
Administration:Intravenous injection (i.v.), single dose, imaging performed at 60 minutes post-injection
-
Result:Exhibited CXCR4-specific tumor accumulation, with low uptake in background organs.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS. Nr. 1341207-62-2
-
Appearance Solid
-
Molecular Weight 1221.36
-
Formel C60H80N14O14
-
Color White to off-white
-
Sequence
Cyclo{Arg-{2-Naph-Ala}-Gly-dTyr-dOrn(NMe)}-PAMBA-DOTA
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Sealed storage, away from moisture and light
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Adv Sci (Weinh)
Mapping CSC-Mediated Ovarian Cancer Chemoresistance via CXCR4-PET to Guide Precision Cisplatin Re-Sensitization Therapy. [Abstract]2026 Apr;13(19):e21279. PMID: 41632105 -
EJNMMI Radiopharm Chem
Increasing the activity output and optimization of automated radiosynthesis [68Ga]Ga-DOTATATE, [68Ga]Ga-Pentixafor, and [68Ga]Ga-FAPI-64 using two [68Ge]Ge/[68Ga]Ga iThemba generators in series. [Abstract]2026 Feb 17;11(1):16. PMID: 41701433
Lösungsmittel & Löslichkeit
Methanol : ≥ 125 mg/mL (102.34 mM)
DMSO : 100 mg/mL (81.88 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Reinheit & Dokumentation
-
Data Sheet (278 KB)
-
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Buck AK, et al. CXCR4-targeted theranostics in oncology. Eur J Nucl Med Mol Imaging. 2022 Oct;49(12):4133-4144. [Content Brief]
[2]. Schwarzenböck SM, et al. [68Ga]pentixafor for CXCR4 imaging in a PC-3 prostate cancer xenograft model - comparison with [18F]FDG PET/CT, MRI and ex vivo receptor expression. Oncotarget. 2017 Sep 16;8(56):95606-95619. [Content Brief]
[3]. Chen Z, et al. Nuclear Medicine Application of Pentixafor/Pentixather Targeting CXCR4 for Imaging and Therapy in Related Disease. Mini Rev Med Chem. 2023;23(7):787-803. [Content Brief]
[4]. Poschenrieder A, et al. First 18F-Labeled Pentixafor-Based Imaging Agent for PET Imaging of CXCR4 Expression In Vivo. Tomography. 2016 Jun;2(2):85-93. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO / Methanol | 1 mM | 0.8188 mL | 4.0938 mL | 8.1876 mL | 20.4690 mL |
| 5 mM | 0.1638 mL | 0.8188 mL | 1.6375 mL | 4.0938 mL | |
| 10 mM | 0.0819 mL | 0.4094 mL | 0.8188 mL | 2.0469 mL | |
| 15 mM | 0.0546 mL | 0.2729 mL | 0.5458 mL | 1.3646 mL | |
| 20 mM | 0.0409 mL | 0.2047 mL | 0.4094 mL | 1.0234 mL | |
| 25 mM | 0.0328 mL | 0.1638 mL | 0.3275 mL | 0.8188 mL | |
| 30 mM | 0.0273 mL | 0.1365 mL | 0.2729 mL | 0.6823 mL | |
| 40 mM | 0.0205 mL | 0.1023 mL | 0.2047 mL | 0.5117 mL | |
| 50 mM | 0.0164 mL | 0.0819 mL | 0.1638 mL | 0.4094 mL | |
| 60 mM | 0.0136 mL | 0.0682 mL | 0.1365 mL | 0.3411 mL | |
| 80 mM | 0.0102 mL | 0.0512 mL | 0.1023 mL | 0.2559 mL | |
| Methanol | 100 mM | 0.0082 mL | 0.0409 mL | 0.0819 mL | 0.2047 mL |
Pentixafor Related Classifications
HY-153549 Related Classifications
Powered by Bioz